China Cord Blood Corporation(CO)- NYSE
  • Mon, Aug. 22, 4:17 PM
    • China Cord Blood (NYSE:CO): FQ1 EPS of $0.03 in-line.
    • Revenue of $26.03M (-2.4% Y/Y) misses by $0.2M.
    • Press Release
    | Mon, Aug. 22, 4:17 PM
  • Wed, Jun. 15, 6:20 AM
    • China Cord Blood (CO) FQ4 results: Revenues: 156.8M (-3.8%); Operating Expense: 82.5M (+4.4%); Operating Income: 39.7M (-19.8%); Net Income: 8.2M (-51.5%); EPS: 0.18 (-21.7%); CF Ops: 138.9M (-5.1%).
    • FY2016 results: Revenues: 663M (+4.4%); Operating Expense: 327.1M (+21.4%); Operating Income: 191.3M (-18.6%); Net Income: 91M (-15.2%); EPS: 1.25 (-8.1%); Quick Assets: 3008.4M (+23.5%); CF Ops: 581M (-2.3%).
    • No guidance given.
    | Wed, Jun. 15, 6:20 AM
  • Tue, Jun. 14, 4:18 PM
    • China Cord Blood (NYSE:CO): FQ4 EPS of $0.03 in-line.
    • Revenue of $24.3M (-7.6% Y/Y) misses by $1.57M.
    • Press Release
    | Tue, Jun. 14, 4:18 PM
  • Mon, Feb. 29, 4:27 PM
    • China Cord Blood (NYSE:CO): Q4 EPS of $0.10 beats by $0.05.
    • Revenue of $26.15M (-2.6% Y/Y) misses by $0.85M.
    | Mon, Feb. 29, 4:27 PM
  • Nov. 24, 2015, 7:50 AM
    • China Cord Blood (CO +0.8%) FQ2 results (NYSEARCA:RMB): Revenues: 171.5M (+12.8%); R&D Expense: 2.2M (-4.3%); SG&A: 79.6M (+28.4%); Operating Income: 52.5M (-8.7%); Net Income: 18.7M (-31.3%); EPS: 0.25 (-28.6%); Quick Assets: 2,436.7M (-8.8%).
    • No guidance given.
    | Nov. 24, 2015, 7:50 AM
  • Nov. 23, 2015, 4:21 PM
    • China Cord Blood (NYSE:CO): FQ2 EPS of $0.04 in-line.
    • Revenue of $26.98M (+8.9% Y/Y) beats by $0.56M.
    | Nov. 23, 2015, 4:21 PM
  • Aug. 20, 2015, 8:00 AM
    • China Cord Blood (CO -2.1%) FQ1 results (NYSEARCA:RMB): Revenues: 165.4M (+7.9%); Gross Profit: 128.8M (+4.2%); Operating Expenses: 80.4M (+26.8%); Operating Income: 48.4M (-19.6%); Net Income: 13.6M (-54.2%); EPS: 0.19 (-48.6%); Quick Assets: 2,560.9M (+5.1%); CF Ops: 130.1M (+4.4%).
    • No guidance given.
    | Aug. 20, 2015, 8:00 AM
  • Aug. 19, 2015, 4:06 PM
    • China Cord Blood (NYSE:CO): FQ1 EPS of $0.03 misses by $0.01.
    • Revenue of $26.7M (+8.0% Y/Y) beats by $0.89M.
    | Aug. 19, 2015, 4:06 PM | 1 Comment
  • Aug. 6, 2015, 9:15 AM
    | Aug. 6, 2015, 9:15 AM | 9 Comments
  • Aug. 6, 2015, 8:27 AM
    • Thinly traded micro cap China Cord Blood (NYSE:CO) is up 26% premarket on increased volume in response to its announcement that it received a non-binding acquisition proposal letter from Nanjing Xinjiekou Department Store Co., Ltd. offering to buy the firm at a price no lower than RMB6.0B ($960M), to be paid in cash or a combination of cash and stock.
    • The special committee of the company's board of directors will carefully assess the proposal.
    | Aug. 6, 2015, 8:27 AM | 4 Comments
  • Jul. 6, 2015, 1:11 PM
    • Thinly traded small cap China Cord Blood (CO -15.2%) is down on double normal volume, albeit on turnover of only 612K shares. No particular news accounts for the move. Management has been mulling a bid for the company by Golden Meditech Holdings.
    | Jul. 6, 2015, 1:11 PM | 2 Comments
  • Jul. 6, 2015, 12:49 PM
    | Jul. 6, 2015, 12:49 PM | 2 Comments
  • Jul. 2, 2015, 9:07 AM
    • Onconova (NASDAQ:ONTX) upgraded to Overweight from Neutral with a $6 (131% upside) price target (up from $3) by Piper Jaffray.
    • BioCryst Pharmaceuticals (NASDAQ:BCRX) upgraded to Buy from Neutral with a $19 (30% upside) price target (up from $12) by Bank of America.
    • Kythera Biopharmaceuticals (NASDAQ:KYTH) downgraded to Market Perform from Outperform with a $65 (13% downside risk) price target (up from $61) by Leerink Swann.
    • Zoetis (NYSE:ZTS) downgraded to Market Perform from Outperform with a $57 (18% upside) price target (up from $51) by BMO.
    • China Cord Blood (NYSE:CO) downgraded to Neutral from Buy with a $6.75 (9% upside) price target (up from $6.50) by Roth Capital.
    • Teladoc (Pending:TDOC) initiated with Outperform rating and $35 (23% upside) price target by RBC.
    • Aldeyra (NASDAQ:ALDX) initiated with Buy rating and $16 (93% upside) price target by Canaccord Genuity.
    • Novagen (NASDAQ:NVGN) initiated with Buy rating and $8.50 (89% upside) price target by H.C. Wainwright.
    | Jul. 2, 2015, 9:07 AM | 10 Comments
  • Jun. 18, 2015, 4:45 PM
    • China Cord Blood (NYSE:CO) fiscal Q4 results ($M): Revenues: 26.3 (+7.3%); Operating Income: 8.0 (-22.7%); Net Income: 2.7 (-57.2%); CF Ops: 23.6 (+6.6%).
    • New subscribers: 15,982; Accumulated subscriber base: 441,359.
    • The company will host its conference call tomorrow morning at 8:00 am ET.
    • Shares are up 3% after hours on light volume.
    | Jun. 18, 2015, 4:45 PM
  • Jun. 18, 2015, 4:03 PM
    • China Cord Blood (NYSE:CO): FQ4 EPS of $0.04 misses by $0.01.
    • Revenue of $26.3M (+7.6% Y/Y) beats by $0.42M.
    | Jun. 18, 2015, 4:03 PM
  • Jun. 17, 2015, 1:30 PM
    • China Cord Blood (CO +5.3%) breaks out of consolidation on a 5x surge in volume. No particular news accounts for the move other than tomorrow's earnings announcement after the close. Consensus views for fiscal Q4 and fiscal 2015 are EPS of $0.05 (-28.6%) and $0.24 on revenues of $25.9M (+6.1%) and $103.3M, respectively.
    • The conference call will start at 8:00 am ET on Friday, June 19.
    | Jun. 17, 2015, 1:30 PM